Foghorn Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
De winst van Foghorn Therapeutics zal naar verwachting dalen met 2.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 32.1% per jaar. De winst per aandeel zal naar verwachting groeien met 5.9% per jaar.
Belangrijke informatie
-2.8%
Groei van de winst
5.9%
Groei van de winst per aandeel
Biotechs winstgroei | 28.3% |
Inkomstengroei | 32.1% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 05 Nov 2024 |
Recente toekomstige groei-updates
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Recent updates
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 07Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk
Oct 22Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up
Sep 01Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking
Jul 17Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
May 09Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 38 | -110 | -110 | -84 | 6 |
12/31/2025 | 34 | -91 | -89 | -90 | 8 |
12/31/2024 | 27 | -91 | -95 | -100 | 6 |
9/30/2024 | 26 | -91 | -104 | -103 | N/A |
6/30/2024 | 35 | -86 | -110 | -110 | N/A |
3/31/2024 | 34 | -93 | -117 | -116 | N/A |
12/31/2023 | 34 | -98 | -119 | -118 | N/A |
9/30/2023 | 33 | -103 | -121 | -119 | N/A |
6/30/2023 | 22 | -115 | -114 | -112 | N/A |
3/31/2023 | 21 | -112 | -111 | -109 | N/A |
12/31/2022 | 19 | -109 | 192 | 194 | N/A |
9/30/2022 | 16 | -109 | 233 | 234 | N/A |
6/30/2022 | 9 | -109 | 233 | 234 | N/A |
3/31/2022 | 5 | -105 | 243 | 244 | N/A |
12/31/2021 | 1 | -101 | -54 | -50 | N/A |
9/30/2021 | 1 | -93 | -84 | -73 | N/A |
6/30/2021 | 1 | -85 | -65 | -50 | N/A |
3/31/2021 | 1 | -78 | -61 | -44 | N/A |
12/31/2020 | 0 | -69 | -47 | -31 | N/A |
9/30/2020 | 0 | -63 | -43 | -34 | N/A |
6/30/2020 | N/A | -58 | -52 | -49 | N/A |
3/31/2020 | N/A | -54 | -48 | -47 | N/A |
12/31/2019 | N/A | -51 | -47 | -46 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat FHTX de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat FHTX de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat FHTX de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van FHTX ( 32.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van FHTX ( 32.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van FHTX naar verwachting over 3 jaar hoog zal zijn